Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

NCT05872685 | Recruiting Phase 2

• 1 other identifier: IIT20230020C-R1
• Study Type: interventional
• Target: 314
• Locations: 1 country
• Sites: 5

Brief Summary

This phase II study is a prospective, multi-center, double-blinded, and randomized trial to compare the efficacy and safety of perioperative SOX plus serplulimab with SOX plus placebo for locally advanced gastric adenocarcinoma with proficient mismatch repair

Conditions

Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction; Proficient Mismatch Repair

Keywords

Gastric Adenocarcinoma; Perioperative Chemotherapy; Serplulimab; Proficient mismatch repair

Outcome Measures

Primary Outcomes (1)

• Rate of pathological complete responses (pCR)

  Percentage of patients with pCR referring to the total number of enrolled and eligible patients, as evaluated centrally by a reference pathologist.

  From enrollment to surgery after pre-operative treatment (up to approximately 36 months)

Secondary Outcomes (3)

• Overall survival

  From enrollment to the end of follow up or death from any cause (up to approximately 60 months)

• Progression-free survival

  From enrollment to the end of follow up or the time of disease progression or relapse or death from any cause (up to approximately 60 months)

• The incidences and types of adverse events (AE) and severe adverse events (SAE)

  From enrollment to 90-day after the last dose administration (up to approximately 27 months)

Study Arms (2)

Group A (Chemotherapy+Serplulimab )

EXPERIMENTAL

Drug: Oxaliplatin，S-1，Serplulimab Chemotherapy (SOX): Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery. Serplulimab: 300 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.

Drug: S1; Drug: Oxaliplatin; Drug: Serplulimab

Group B (Chemotherapy+Placebo )

ACTIVE COMPARATOR

Drug: Oxaliplatin，S-1，Placebo Chemotherapy (SOX): Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery. Placebo: 300 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.

Drug: S1; Drug: Oxaliplatin; Drug: Placebo

Interventions

S1 DRUG

S-1 orally intake as perioperative chemotherapy

Group A (Chemotherapy+Serplulimab ); Group B (Chemotherapy+Placebo )

Oxaliplatin DRUG

Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

Group A (Chemotherapy+Serplulimab ); Group B (Chemotherapy+Placebo )

Serplulimab DRUG

Perioperative serplulimab, 300 mg IV infusion

Group A (Chemotherapy+Serplulimab )

Placebo DRUG

Perioperative placebo, 300 mg IV infusion

Group B (Chemotherapy+Placebo )

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF).
• The gender is not limited. Age: ≥ 18 years and ≤ 80 years old.
• Gastric or esophagogastric junction adenocarcinoma confirmed by pathology, and proficient mismatch repair confirmed by immunohistochemistry.
• Clinical stage at presentation: cT2-T4b, N+/-, M0 as determined by AJCC staging system, 8th edition.The definition of metastatic lymph nodes: a lymph node must be ≥ 10mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) according to the guideline of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1)
• Participants with a performance status of 0 \~ 1 on the Eastern Cooperative Oncology Group (ECOG) within 7 days before the first dose of study treatment.
• Life expectancy ≥ 6 months.
• Agreement of providing pretreatment endoscopic biopsies specimens and surgical specimens for biomarker analysis, as well as the peripheral blood, feces and urine sample.
• The functions of the vital organs meet requirements as follow (within 14 days before the first dose of study treatment, participant has not received treatment of recombinant human thrombopoietin or granulocyte stimulating factor):
• Hematological function： White blood cell count (WBC): 3.5 × 10 \^ 9 / L \~12.0 × 10 \^ 9 / L； Absolute neutrophil count (ANC) ≥ 1.5 × 10 \^ 9 / L； Platelet count (PLT) ≥ 100 × 10 \^ 9 / L； Hemoglobin (Hb) ≥ 90 g / L.
• Hepatic function： Total bilirubin (TBIL) ≤ 1.5 × ULN (upper limit of normal); Aspartate aminotransferase (AST) ≤ 2.5 × ULN; Alanine aminotransferase (ALT) ≤ 2.5 × ULN; Albumin (ALB) ≥ 30 g / L.
• Renal function： Creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 60 ml / min for those with creatinine level \> 1.5 × ULN.
• Coagulation function： International normalized ratio (INR) ≤ 1.5; Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
• Female of childbearing age must meet requirements: urine or serum pregnancy test must be negative within 7 days before the first dose of study treatment, and she must agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of serplulimab, or 180 days after the last dose of chemotherapy, whichever is longer, and should not be breastfeeding.
• For the male participants must meet requirements: agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of serplulimab, or 180 days after the last dose of chemotherapy, whichever is longer).

You may not qualify if:

• HER2-positive, EBER-positive or dMMR.
• Prior systemic therapy for treatment of gastric cancer (surgery, chemotherapy, radiotherapy, targeted therapy or immunotherapy).
• Previous or concurrent have other active malignant tumors within the past 5 years (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy).
• Participants with gastric outlet obstruction, or unable for oral take, or severe gastrointestinal bleeding.
• Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV).
• Existence of chronic diarrhea (watery diarrhea: ≥ 5 times per day).
• Participants with active infection within 14 days before the first dose of study treatment which need medical intervention.
• Participants with active tuberculosis.
• Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms.
• Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody.
• Participants who need long-term systemic steroid therapy (\> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period.
• Concurrent or previous have severe allergic reaction to any antibody-based drugs.
• Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy.
• Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza.
• Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.

Sponsors & Collaborators

• Yu jiren: lead

Study Sites (5)

The First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China

RECRUITING

The Second Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China

NOT YET RECRUITING

Lishui Central Hospital

Lishui, Zhejiang, 323000, China

NOT YET RECRUITING

Ningbo Medical Center LiHuiLi Hospital

Ningbo, Zhejiang, 315048, China

NOT YET RECRUITING

Taizhou Hospital

Taizhou, Zhejiang, 317099, China

NOT YET RECRUITING

MeSH Terms

Interventions

S 1 (combination); Oxaliplatin

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals

Central Study Contacts

Jiren Yu

CONTACT

+86-0571-87236147; yujr0909@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 14, 2023
• First Posted: May 24, 2023
• Study Start: December 24, 2023
• Primary Completion: April 30, 2026
• Study Completion (Estimated): April 30, 2029
• Last Updated: January 17, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (5)